{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:11:20Z","timestamp":1790442680348,"version":"4.1.0"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01408, PI22\/01834"],"award-info":[{"award-number":["PI19\/01408, PI22\/01834"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["823854 (INNOVA4TB)"],"award-info":[{"award-number":["823854 (INNOVA4TB)"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Cooperation Science and Technology","award":["COST Action CA21164"],"award-info":[{"award-number":["COST Action CA21164"]}]},{"name":"MSCA4Ukraine","award":["ID:1233336"],"award-info":[{"award-number":["ID:1233336"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with multidrug-resistant tuberculosis (MDR-TB) receive treatment that is at least 20% less effective than drug-susceptible cases globally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The study evaluated the diagnostic accuracy of mfloDx MDR-TB assay (EMPE Diagnostics AB, Solna, Sweden) for simultaneous detection of resistance to isoniazid (INH) and rifampicin (RIF) compared to culture-based drug susceptibility test (DST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A prospective diagnostic accuracy study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Clinical samples from 287 patients (mean age 45.3 (95% CI 43.3\u201347.2) years; 50 (17.0%) were female) from TB facilities in Ukraine (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200982, 28.6%), Moldova (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200937, 12.9%) and Spain (168, 58.5%) with bacteriologically confirmed TB and persons evaluated for non-tuberculous mycobacteria (NTM) were consecutively tested. The results of the mfloDx MDR-TB assay were compared with culture-based DST.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 186 out of 287 sputum specimens (64.8%) yielded conclusive results that allowed a definitive interpretation of resistance to at least one drug. The mfloDx MDR-TB assay demonstrated sensitivity at 86.9 (95% CI 80.6\u201391.7) and specificity at 100 (95% CI 79.4\u2013100) correctly differentiating mycobacterium tuberculosis complex from NTM in smear positive sputum samples. Considering only conclusive results in sputum samples, the mfloDx MDR-TB assay simultaneously predicted resistance to INH and RIF in TB patients showing high sensitivity 100 (95% CI 93.0\u2013100) and specificity 98.7 (95% CI 92.8\u2013100) compared to MDR-TB detection by culture-based DST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>While approximately one-third of tests yielded inconclusive results, the mfloDx\u2122 MDR-TB assay demonstrated potential as a rapid screening tool for INH and RIF resistance, offering a time advantage over conventional culture-based DST.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20499361261436542","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T12:37:24Z","timestamp":1776515844000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A new multiplex molecular assay based on padlock probes and rolling circle amplification for MDR-TB detection in clinical specimens: a prospective diagnostic accuracy study"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8780-9480","authenticated-orcid":false,"given":"Andrii","family":"Dudnyk","sequence":"first","affiliation":[{"name":"Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain"},{"name":"Department of Tuberculosis, Clinical Immunology and Allergy, National Pirogov Memorial Medical University, Vinnytsia, Ukraine"},{"name":"Serveis Cl\u00ednics, Carrer de Garc\u00eda Mari\u00f1o, 4, Sarri\u00e0-Sant Gervasi, 08022 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiia","family":"Tytarenko","sequence":"additional","affiliation":[{"name":"Germans Trias i Pujol Research Institute (IGTP); Badalona, Barcelona, Spain"},{"name":"Odesa I. I. Mechnikov National University, Odesa, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Lytvyniuk","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Clinical Immunology and Allergy, National Pirogov Memorial Medical University, Vinnytsia, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Tolstova","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory, Regional Phthisiopulmonology Center, Vinnytsia, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan-Pau","family":"Millet","sequence":"additional","affiliation":[{"name":"Serveis Clinics, Barcelona, Spain"},{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica, CIBEREESP, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Molina","sequence":"additional","affiliation":[{"name":"Serveis Clinics, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Antuori","sequence":"additional","affiliation":[{"name":"Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain"},{"name":"Microbiology Department, Laboratori Cl\u00ednic Metropolitana Nord (LCMN), Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Ciobanu","sequence":"additional","affiliation":[{"name":"PMSI Institute of Pneumology \u201cChiril Draganiuc,\u201d Chi\u0219in\u0103u, Moldova"},{"name":"Department of Pneumology &amp; Allergology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriu","family":"Crudu","sequence":"additional","affiliation":[{"name":"PMSI Institute of Pneumology \u201cChiril Draganiuc,\u201d Chi\u0219in\u0103u, Moldova"},{"name":"Department of Pneumology &amp; Allergology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Germans Trias i Pujol Research Institute (IGTP); Badalona, Barcelona, Spain"},{"name":"Department of Genetics and Microbiology, Universitat Aut\u00f2noma de Barcelona, Badalona, Barcelona, Spain"},{"name":"CIBER Enfermedades Respiratorias, CIBERES, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Political Declaration of the High-level Meeting on Antimicrobial Resistance. UN general assembly high-level meeting on antimicrobial resistance 2024 https:\/\/www.un.org\/pga\/wp-content\/uploads\/sites\/108\/2024\/09\/FINAL-Text-AMR-to-PGA.pdf (2024 accessed 14 February 2026)."},{"key":"e_1_3_4_3_2","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment 2022 update. Geneva: World Health Organization. https:\/\/www.who.int\/publications\/i\/item\/9789240063129 (2022 accessed 14 September 2023)."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003008"},{"key":"e_1_3_4_5_2","unstructured":"Global tuberculosis report 2025. Geneva: World Health Organization 2025. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/e97dd6f4-b567-4396-8680-717bac6869a9\/content."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00065311"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00875-1"},{"key":"e_1_3_4_8_2","unstructured":"Attacks on Health Care in Ukraine https:\/\/www.attacksonhealthukraine.org\/ (accessed 22 October 2024)."},{"key":"e_1_3_4_9_2","unstructured":"WHO consolidated guidelines on tuberculosis. Module 3: diagnosis \u2013 rapid diagnostics for tuberculosis detection. 3rd ed. Geneva: World Health Organization 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376221\/9789240089488-eng.pdf?sequence=1."},{"key":"e_1_3_4_10_2","unstructured":"TestdirExplorer https:\/\/finddx.shinyapps.io\/testdirexplorer_beta\/ (accessed 22 March 2026)."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2022.102199"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02295-w"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.71313"},{"key":"e_1_3_4_14_2","unstructured":"WHO operational handbook on tuberculosis. Module 3: diagnosis. Geneva: World Health Organization; 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240110991."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106621"},{"key":"e_1_3_4_16_2","unstructured":"POC for detecting drug resistance. INNOVA4TB https:\/\/www.innova4tb.com\/poc-for-detecting-drug-resistance (2019 accessed 26 August 2025)."},{"key":"e_1_3_4_17_2","unstructured":"Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis Geneva: World Health Organization 2018. https:\/\/apps.who.int\/iris\/handle\/10665\/275469 (accessed 20 July 2023)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012799"},{"key":"e_1_3_4_19_2","unstructured":"R Core Team (2023). R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna Austria https:\/\/www.R-project.org\/."},{"key":"e_1_3_4_20_2","unstructured":"European Centre for Disease Prevention and Control WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2024 \u2013 2022 data. Copenhagen: WHO Regional Office for Europe and Stockholm: European Centre for Disease Prevention and Control; 2024. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/TB_Surveillance_Report_2024.pdf."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmy.ijmy_21_24"},{"key":"e_1_3_4_22_2","unstructured":"World Health Organization. Target product profiles for tuberculosis diagnosis and detection of drug resistance. Geneva: World Health Organization 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/378358\/9789240097698-eng.pdf?sequence=1."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050090"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-4817-2"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6738095"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2022.100342"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00618-08"},{"key":"e_1_3_4_28_2","unstructured":"WHO announces first prequalification of a tuberculosis diagnostic test https:\/\/www.who.int\/news\/item\/05-12-2024-who-announces-first-prequalification-of-a-tuberculosis-diagnostic-test (2024 accessed 9 December 2024)."},{"key":"e_1_3_4_29_2","article-title":"Factors influencing false-positive results of rifampicin resistance detected by Xpert MTB\/RIF: a retrospective study in Zhejiang, China","volume":"10","author":"Wu G","year":"2024","unstructured":"Wu G, Wang J, Xu X, et al. Factors influencing false-positive results of rifampicin resistance detected by Xpert MTB\/RIF: a retrospective study in Zhejiang, China. Heliyon 2024; 10: e31680.","journal-title":"Heliyon"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2018.06.011"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251602"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.12701\/jyms.2024.00024"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202312-1076OC"},{"key":"e_1_3_4_34_2","unstructured":"WHO consolidated guidelines on tuberculosis. Module 1: prevention \u2013 tuberculosis preventive treatment. 2nd ed. Geneva: World Health Organization 2024."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21025-6"},{"key":"e_1_3_4_36_2","unstructured":"Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians. Geneva: World Health Organization 2022."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2019.12.002"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361261436542","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361261436542","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361261436542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:02:07Z","timestamp":1777593727000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361261436542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"alternative-id":["10.1177\/20499361261436542"],"URL":"https:\/\/doi.org\/10.1177\/20499361261436542","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"20499361261436542"}}